fluorodeoxyglucose f18 has been researched along with panobinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhalla, KN; Bishton, M; DeAngelo, DJ; Dickinson, M; Fischer, T; Liu, A; Ottmann, OG; Parker, K; Prince, HM; Ritchie, D; Scott, JW; Spencer, A | 1 |
| Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W | 1 |
2 trial(s) available for fluorodeoxyglucose f18 and panobinostat
| Article | Year |
|---|---|
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Panobinostat; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Topics: Acetylation; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Panobinostat; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |